JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pfizer

Suletud

SektorTervishoid

24.59 0.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.55

Max

24.91

Põhinäitajad

By Trading Economics

Sissetulek

2.6B

3B

Müük

-4B

14B

P/E

Sektori keskmine

17.051

34.393

Aktsiakasum

0.92

Dividenditootlus

7.19

Kasumimarginaal

21.677

Töötajad

81,000

EBITDA

2.5B

5.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+16.31% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

7.19%

2.54%

Järgmine tulemuste avaldamine

28. okt 2025

Järgmine dividendimakse kuupäev

2. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-12B

134B

Eelmine avamishind

24.55

Eelmine sulgemishind

24.59

Uudiste sentiment

By Acuity

39%

61%

125 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. aug 2025, 11:34 UTC

Tulu

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5. aug 2025, 20:44 UTC

Tulu

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 18:20 UTC

Tulu

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. aug 2025, 18:17 UTC

Tulu

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. aug 2025, 16:04 UTC

Market Talk

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5. aug 2025, 15:25 UTC

Tulu

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. aug 2025, 13:56 UTC

Tulu

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. aug 2025, 11:43 UTC

Tulu

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5. aug 2025, 11:27 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:57 UTC

Tulu

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5. aug 2025, 10:55 UTC

Tulu

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. aug 2025, 10:53 UTC

Tulu

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5. aug 2025, 10:51 UTC

Tulu

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5. aug 2025, 10:50 UTC

Tulu

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5. aug 2025, 10:49 UTC

Tulu

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5. aug 2025, 10:49 UTC

Tulu

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5. aug 2025, 10:48 UTC

Tulu

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5. aug 2025, 10:48 UTC

Tulu

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5. aug 2025, 10:47 UTC

Tulu

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5. aug 2025, 10:46 UTC

Tulu

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer Raises 2025 EPS Guidance >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer 2Q EPS 51c >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer 2Q Adj EPS 78c >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer 2Q Rev $14.7B >PFE

5. aug 2025, 10:45 UTC

Tulu

Pfizer Sees FY Rev $61B-$64B >PFE

4. aug 2025, 15:26 UTC

Tulu

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30. juuli 2025, 18:36 UTC

Tulu

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9. juuli 2025, 09:17 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10. juuni 2025, 12:18 UTC

Tulu

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

16.31% tõus

12 kuu keskmine prognoos

Keskmine 28.59 USD  16.31%

Kõrge 33 USD

Madal 24 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

6

Osta

12

Hoia

0

Müü

Tehniline skoor

By Trading Central

22.855 / 23.85Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

125 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.